[Form 4] Lumentum Holdings Inc. Insider Trading Activity
Rhea-AI Filing Summary
Insider transactions by Jae Kim at Lumentum Holdings (LITE): The reporting person, SVP and General Counsel Jae Kim, sold a total of 4,507 shares of Lumentum common stock on 08/22/2025 in two sets of sales (3,407 and 1,100 shares) under a Rule 10b5-1 plan at weighted average prices of $116.7274 and $117.3564, respectively. On 08/23/2025 the reporting person was credited with 7,715 restricted stock units (RSUs) that convert to common shares upon vesting, bringing the reported beneficial ownership to 41,180 shares. The RSUs vest 100% on August 23, 2026, subject to continued employment.
Positive
- Received 7,715 RSUs that vest 100% on August 23, 2026, aligning the reporting person’s interests with long-term shareholder outcomes
- Sales executed under a Rule 10b5-1 plan, which provides an affirmative defense and indicates preplanned disposition timing
Negative
- Sold 4,507 shares on 08/22/2025, reducing immediate direct holdings (sales executed at weighted average prices of $116.7274 and $117.3564)
- Reported beneficial ownership remains modest at 41,180 shares after transactions (no additional indirect holdings disclosed)
Insights
TL;DR: Insider sold shares under a 10b5-1 plan and received an RSU award vesting in one year; transaction is routine but worth monitoring.
The Form 4 shows Jae Kim executed preplanned sales under a Rule 10b5-1 trading plan adopted February 11, 2025, with weighted average sale prices reported and an undertaking to provide trade-level detail if requested. The grant of 7,715 RSUs, vesting 100% on August 23, 2026, is a standard equity compensation event that increases reported beneficial ownership when converted. From a governance perspective, the presence of a 10b5-1 plan clarifies the timing of sales and reduces concerns about selective insider timing, while the RSU grant aligns the officer's interests with long-term shareholder value.
TL;DR: Sales and a compensatory RSU award offset to leave reported beneficial ownership at 41,180 shares; transactions appear procedural, not material financial news.
Quantitatively, the Form 4 reports sales of 3,407 and 1,100 shares executed at weighted average prices in the $116.24–$117.60 range and a contemporaneous grant of 7,715 RSUs that vest in one year. The reporting person discloses willingness to provide full trade details to regulators or shareholders, suggesting no omission of execution prices. For market impact, these filings are routine executive compensation and preplanned disposition activity rather than operational developments affecting company fundamentals.